(R)-3,5-dimethylbenzoic acid N-(1-tert-butylbutyl)-N'-(3-methoxy-2-methylbenzoyl)hydrazide | 1093131-01-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-3,5-dimethylbenzoic acid N-(1-tert-butylbutyl)-N'-(3-methoxy-2-methylbenzoyl)hydrazide
• 英文别名: N'-(3,5-dimethylbenzoyl)-N'-[(3R)-2,2-dimethylhexan-3-yl]-3-methoxy-2-methylbenzohydrazide
• CAS: 1093131-01-1
• 化学式: C₂₆H₃₆N₂O₃
• 分子量: 424.583
• InChiKey: SLUCGBVQOKHSKK-HSZRJFAPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
  申请人：HORMANN Robert Eugene

  公开号：US20120116090A1

  公开（公告）日：2012-05-10

  The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.

  本发明提供了用于基于蜕皮激素受体的诱导基因表达系统的二酰肼配体和手性二酰肼配体。因此，本发明适用于基因治疗、大规模蛋白质和抗体生产、基于细胞的筛选分析、功能基因组学、蛋白质组学、代谢组学和转基因生物特征调控等应用中，其中需要控制基因表达水平。本发明的优点在于提供了一种调节基因表达并根据用户要求定制表达水平的手段。
• Boron-Containing Diacylhydrazines
  申请人：Intrexon Corporation

  公开号：US20150322092A1

  公开（公告）日：2015-11-12

  The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , and R 5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

  本公开提供具有I式的含硼二酰肼化合物及其药学上可接受的盐和溶剂化物，其中R1、R2、R3、R4和R5的定义如规范中所述。本公开还提供了使用含硼二酰肼化合物的ecdysone受体基础的诱导基因表达系统。因此，本公开适用于基因治疗、疾病治疗、大规模生产蛋白质和抗体、基于细胞的筛选测定、功能基因组学、蛋白质组学、代谢组学和调控转基因生物的特征等应用，其中需要控制基因表达水平。
• Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
  申请人：Hormann Robert Eugene

  公开号：US20090163592A1

  公开（公告）日：2009-06-25

  The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.

  本发明提供了用于基于蜕皮激素受体诱导基因表达系统的二酰肼配体和手性二酰肼配体。因此，本发明可用于基因治疗、大规模蛋白质和抗体生产、细胞筛选分析、功能基因组学、蛋白质组学、代谢组学和转基因生物特征调控等应用中，其中需要控制基因表达水平。本发明的优点是提供了一种调节基因表达并根据用户要求调整表达水平的手段。
• CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX
  申请人：Intrexon Corporation

  公开号：EP3357904A1

  公开（公告）日：2018-08-08

  The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.

  本发明提供了二酰肼配体和手性二酰肼配体，可用于基于蜕皮激素受体的诱导基因表达系统。因此，本发明可用于基因治疗、蛋白质和抗体的大规模生产、基于细胞的筛选测定、功能基因组学、蛋白质组学、代谢组学以及转基因生物的性状调控等应用，在这些应用中，需要对基因表达水平进行控制。本发明的一个优点是提供了一种调节基因表达和定制表达水平以满足用户要求的方法。
• Boron-containing diacylhydrazines
  申请人：Intrexon Corporation

  公开号：US10464951B2

  公开（公告）日：2019-11-05

  The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

  本公开提供了具有式 I 的含硼二酰肼： 及其药学上可接受的盐和溶液，其中 R1、R2、R3、R4 和 R5 的定义如说明书所述。本公开还提供了含硼二酰肼在基于蜕皮激素受体的诱导基因表达系统中的用途。因此，本公开可用于基因治疗、疾病治疗、蛋白质和抗体的大规模生产、基于细胞的筛选测定、功能基因组学、蛋白质组学、代谢组学以及转基因生物的性状调控等需要控制基因表达水平的应用领域。